Cargando…
Editorial Commentary: Comparative Efficacy of Lamivudine and Emtricitabine: Comparing the Results of Randomized Trials and Cohorts
Autores principales: | Ford, Nathan, Hill, Andrew, Vitoria, Marco, Mills, Edward J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264583/ https://www.ncbi.nlm.nih.gov/pubmed/25273083 http://dx.doi.org/10.1093/cid/ciu767 |
Ejemplares similares
-
Editorial Commentary: Immunodeficiency at Start of Antiretroviral Therapy: The Persistent Problem of Late Presentation to Care
por: Ford, Nathan, et al.
Publicado: (2015) -
SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen
por: Campo, R., et al.
Publicado: (2013) -
Comparative Efficacy of Lamivudine and Emtricitabine: A Systematic Review and Meta-Analysis of Randomized Trials
por: Ford, Nathan, et al.
Publicado: (2013) -
Real-Life Experience With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Turkey
por: Balcı, Umay, et al.
Publicado: (2023) -
Editorial Commentary: The Irreversibility of HIV Drug Resistance
por: Kouyos, Roger D., et al.
Publicado: (2015)